Evaluation of biomaterial scaffold delivery of IL-33 as a localized immunomodulatory agent to support cell transplantation in adipose tissue
Journal of Immunology and Regenerative Medicine · 2018
DOI: 10.1016/j.regen.2018.01.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology and Regenerative Medicine, 2018. Verfasst von Jeffrey M H Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Biological Sciences Program, Northwestern University, Evanston, IL, 60208, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
INTRODUCTION: The development of novel immunomodulatory strategies that might decrease the need for systemic immune suppression would greatly enable the utility of cell-based therapies. Cell transplantation on biomaterial scaffolds offers a unique opportunity to engineer a site to locally polarize immunogenic antigen generation. Herein, we investigated the localized delivery of IL-33, which is a novel cytokine that has been shown to have beneficial immunomodulatory effects in certain transplant models as mediating anti-inflammatory properties in the adipose tissue, to determine its feasibility for use as an immunomodulatory agent. RESULTS: Localized IL-33 delivery from poly(lactide-co-glycolide) (PLG) scaffolds implanted into the epididymal fat specifically increased the Foxp3+ population of CD4+ T cells in both blank scaffold implants and scaffolds seeded with allogeneic islets. In allogeneic islet transplantation, we found IL-33 delivery results in a local upregulation of graft-protective T cells where 80% of the local CD4+ population is Foxp3+ and overall numbers of graft destructive CD8+ T cells are decreased, resulting in a prolonged graft survival. Interestingly, local IL-33 also delayed islet engraftment by primarily inducing a local upregulation of Th2 cytokines, including IL-4 and IL-5, leading to increased populations of ST2+ Type 2 innate lymphoid cells (ILC2s) and Siglec F+ eosinophils. CONCLUSIONS: These results suggest that local IL-33 delivery from biomaterial scaffolds can be used to increase Tregs enriched in adipose tissue and reduce graft-destructive T cell populations but may also promote innate cell populations that can delay cell engraftment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Interdisciplinary Biological Sciences Program, Northwestern University, Evanston, IL, 60208, USA.
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
- Department of Surgery, Division of Transplantation, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- Center for Kidney Research and Therapeutics, Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, IL, 60611, USA.
- Department of Medicine, Division of Nephrology and Hypertension, Northwestern University, Chicago, IL, 60611, USA.
Förderung
- NIDDK NIH HHS
- NIAID NIH HHS
- NIBIB NIH HHS
- NIH
Zitieren
APA
Liu, J. M. H., Zhang, X., Joe, S., Luo, X., & Shea, L. D. (2018). Evaluation of biomaterial scaffold delivery of IL-33 as a localized immunomodulatory agent to support cell transplantation in adipose tissue. Journal of Immunology and Regenerative Medicine. https://doi.org/10.1016/j.regen.2018.01.003
Vancouver
Liu JMH, Zhang X, Joe S, Luo X, Shea LD. Evaluation of biomaterial scaffold delivery of IL-33 as a localized immunomodulatory agent to support cell transplantation in adipose tissue. Journal of Immunology and Regenerative Medicine. 2018. doi:10.1016/j.regen.2018.01.003
BibTeX
@article{Liu2018,
author = {Liu, Jeffrey M H and Zhang, Xiaomin and Joe, Shelby and Luo, Xunrong and Shea, Lonnie D},
title = {Evaluation of biomaterial scaffold delivery of IL-33 as a localized immunomodulatory agent to support cell transplantation in adipose tissue},
journal = {Journal of Immunology and Regenerative Medicine},
year = {2018},
doi = {10.1016/j.regen.2018.01.003}
}
EUVIMED